229 related articles for article (PubMed ID: 36157140)
21. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals.
Belperio PS; Shahoumian TA; Mole LA; Backus LI
Hepatology; 2017 Jul; 66(1):27-36. PubMed ID: 28240789
[TBL] [Abstract][Full Text] [Related]
22. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement.
Tag-Adeen M; Sabra AM; Akazawa Y; Ohnita K; Nakao K
Hepat Med; 2017; 9():45-53. PubMed ID: 29062242
[TBL] [Abstract][Full Text] [Related]
23. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
24. Management Of Patients With Hepatitis B Virus Reactivation Post-DAA Treatment Of Chronic Hepatitis C Virus Infection In HCV-HBV Coinfected Patients With Pretreatment HBeAg Seroconversion And Early Degree Of Hepatic Fibrosis.
Osman HA; Ghweil AA; Sabry AM; Mahdy RE; Khodeary A
Infect Drug Resist; 2019; 12():3067-3073. PubMed ID: 31632097
[TBL] [Abstract][Full Text] [Related]
25. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data.
El Kassas M; Shimakawa Y; Ali-Eldin Z; Funk AL; Wifi MN; Zaky S; El-Raey F; Esmat G; Fontanet A
Liver Int; 2018 Dec; 38(12):2159-2169. PubMed ID: 29738637
[TBL] [Abstract][Full Text] [Related]
26. Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study.
Mücke MM; Mücke VT; Peiffer KH; Sarrazin C; Zeuzem S; Berger A; Vermehren J
Open Forum Infect Dis; 2019 Jan; 6(1):ofy340. PubMed ID: 30648130
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal assessment of hepatic fibrosis in responders to direct-acting antivirals for recurrent hepatitis C after liver transplantation using noninvasive methods.
Omar H; Said M; Eletreby R; Mehrez M; Bassam M; Abdellatif Z; Hosny A; Megawer S; El Amir M; Yosry A
Clin Transplant; 2018 Aug; 32(8):e13334. PubMed ID: 29935046
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
[TBL] [Abstract][Full Text] [Related]
29. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
Tamori A; Abiru S; Enomoto H; Kioka K; Korenaga M; Tani J; Enomoto M; Sugiyama M; Masaki T; Kawada N; Yatsuhashi H; Nishiguchi S; Mizokami M
J Viral Hepat; 2018 May; 25(5):608-611. PubMed ID: 29194858
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
[TBL] [Abstract][Full Text] [Related]
31. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
[TBL] [Abstract][Full Text] [Related]
32. Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas.
Lan TY; Lin YC; Tseng TC; Yang HC; Kao JH; Cheng CF; Lee TJ; Huang SC; Lu CH; Li KJ; Hsieh SC
Gut Liver; 2023 Mar; 17(2):288-298. PubMed ID: 36268584
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
[TBL] [Abstract][Full Text] [Related]
34. Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.
Jaroszewicz J; Pawłowska M; Simon K; Zarębska-Michaluk D; Lorenc B; Klapaczyński J; Tudrujek-Zdunek M; Sitko M; Mazur W; Janczewska E; Paluch K; Dybowska D; Buczyńska I; Czauż-Andrzejuk A; Berak H; Krygier R; Piasecki M; Dobracka B; Citko J; Piekarska A; Socha Ł; Deroń Z; Tronina O; Laurans Ł; Białkowska J; Tomasiewicz K; Halota W; Flisiak R
Expert Rev Anti Infect Ther; 2020 Oct; 18(10):1045-1054. PubMed ID: 32538232
[TBL] [Abstract][Full Text] [Related]
35. Clinical and virological features of chronic hepatitis B in the French national surveillance program, 2008-2012: A cross-sectional study.
Chevaliez S; Roudot-Thoraval F; Brouard C; Gordien E; Zoulim F; Brichler S; Brodard V; Pioche C; Pawlotsky JM; Leroy V;
JHEP Rep; 2022 Dec; 4(12):100593. PubMed ID: 36313185
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
[TBL] [Abstract][Full Text] [Related]
37. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
[TBL] [Abstract][Full Text] [Related]
38. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
[TBL] [Abstract][Full Text] [Related]
39. Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment.
Niu B; Zang W; Zhou H; Mi Y; Lu C; Li P
BMC Gastroenterol; 2023 Apr; 23(1):102. PubMed ID: 37013471
[TBL] [Abstract][Full Text] [Related]
40. Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals.
Alswat K; Al-Sohaibani F; Khathlan A; Bashmail A; Alanazi M; Kurdi A; Almakadma AH; Al-Hamoudi W
Ann Saudi Med; 2022; 42(2):89-95. PubMed ID: 35380056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]